Vertex announces statistically significant and clinically meaningful results from two phase 2 proof-of-concept studies of vx-548 for the treatment of acute pain

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced positive results from two phase 2 proof-of-concept (poc) studies that investigated treatment with the selective nav1.8 inhibitor vx-548 for acute pain following abdominoplasty surgery or bunionectomy surgery. treatment with an initial dose of 100 mg followed by 50 mg every 12 hours of vx-548 (high-dose) compared to placebo resulted in a rapid, statistically significant and clinically meaningful improveme
VRTX Ratings Summary
VRTX Quant Ranking